Prof. Yigal Koltin, Director
Prof. Koltin was trained at Harvard University (Cambridge, MA) where he received his Ph.D.degree in Genetics/Biology and completed also his postdoctoral training. He served for more than 25 years as Professor of Genetics at Tel Aviv University and 30 years in various capacities in the pharmaceutical and the biopharmaceutical industries including former SmithKline and French (today GSK) and Schering Corporation. In 1992 he was a founding member of ChemGenics Pharmaceuticals and served as VP of Cell and Molecular Biology.
After ChemGenics merged in 1997 with Millennium Pharmaceuticals (Cambridge, MA), Prof. Koltin served initially as VP of Cell and Molecular Biology, later as VP of Program Management managing all the pharmaceutical alliances with most of the major pharmaceutical companies world-wide covering 7 diseases. He managed also the strategic development of the internal disease programs. Dr. Koltin directed the infectious disease programs with Pfizer (Sandwich, UK) with Wyeth (Pearl River, US). In his last position at Millennium Pharmaceuticals he served as VP for International R&D Alliance Development in Europe and Israel.
During the last 12 years Prof. Koltin assisted many early stage biopharmaceutical companies and was an advisor to a number of venture capital firms. Prof. Koltin served as Chairman of the BOD of Applied Immune Technologies, serving currently as member of the BOD of Avraham Pharmaceuticals, Sr. consultant to Cliniworks USA, was member of the BOD of RadBio Accelerator, on the BOD of Prontodiagnostics and was the Chairman of the BOD of Applied Immune Technologies that was recently financed by Novartis Venture Fund, Pontifax and the Technion Research Foundation.
Dr. Anne Lo, Director
Dr. Lo represents Horizons Ventures on the board. She trained as a veterinary surgeon and worked in a number of clinical roles, including the Equestrian Events at the Beijing Olympics before taking up a position as Junior Fellow at the Cambridge Infectious Diseases Consortium, specialising in Influenza A virus. She subsequently joined strategy consulting firm Bain & Co' s London office, working on a wide range of private equity and corporate projects. Her last role prior to joining Horizons Ventures was to execute strategic 5 year plan initiatives for Worldpay, a Bain Capital and Advent International portfolio company.
Dr. Lo received her BSc and BVM&S degrees from the University of Edinburgh and PhD from the University of Cambridge in the United Kingdom.
Dr. Michael Schickler
Dr. Schickler brings over 25 years of profound managerial and technological experience in the biopharmaceutical industry. Dr. Schickler has been the CEO of CureTech Ltd. since May 2001 and played a key role in transforming it from a virtual, university-based, entity into an independent company. Prior to that, he also served as Managing Director of Clal Life Sciences L.P., the research center of Clal Biotechnology Industries in Israel which he also helped to establish. Prior thereto, Dr. Schickler held various managerial positions with Pharmos Corporation and was involved in the development of several of Pharmos’s drugs. Prior to joining Pharmos, Dr. Schickler held an academic position with the Volcani Institute, Israel and research position with Hoffmann-La Roche Inc., US. Dr. Schickler earned his Ph.D. from the Weizmann Institute of Science in Israel, has M.Sc. magna cum laude in immunology from Tel-Aviv University, Israel and holds a diploma in business administration from Lincoln University, UK.